SCHEMBL21033308

SCHEMBL21033308

Cc1ccn2nc(C(=O)O)c(F)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 4/20 0.41
▸ PTGS2 P35354 1/20 0.40
▸ TYK2 P29597 1/20 0.37
▸ HCAR2 Q8TDS4 1/20 0.34
▸ KDM4E B2RXH2 4/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ PPARA Q07869 2/20 0.34
▸ PKM P14618 2/20 0.33
▸ ASPH Q12797 1/20 0.33
▸ KDM8 Q8N371 1/20 0.33
▸ ABCC4 O15439 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ PTGS1 P23219 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21033150 0.84 HTR6 (0.39) HTR6PTGS2TYK2KDM4EKMT2A
SCHEMBL21001663 0.84 KDM4E (0.45) HTR6PTGS2TYK2KDM4EKMT2A
SCHEMBL21033227 0.79 TGFBR1 (0.35) KDM4EKMT2AASPHKDM8LMNA
SCHEMBL19147685 0.75 PTGS2 (0.43) PTGS2KDM4EKMT2AMEN1HSD17B10
SCHEMBL18208948 0.74 POLB (0.42) HTR6PTGS2KDM4EKMT2AMEN1
SCHEMBL17883350 0.73 HTR6 (0.38) HTR6PTGS2TYK2KDM4EPKM
SCHEMBL15307034 0.72 HTR6 (0.40) HTR6PTGS2KDM4EKMT2AMEN1
SCHEMBL23013548 0.70 DHODH (0.41) HTR6PTGS2KDM4EHSD17B10LMNA
SCHEMBL29703800 0.70 DHODH (0.41) HTR6PTGS2KDM4EHSD17B10LMNA
SCHEMBL359281 0.69 TYK2 (0.53) TYK2KDM4EKMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111542523-B Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2024-03-29 — — CN disclosed
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC 2021-12-02 — — US disclosed
CN-111542523-A Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2020-08-14 — — CN disclosed
WO-2019102494-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2019-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 HTR6 3187/4885PTGS2 3251/4885TYK2 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback